Scientific letter
HCC-neuroendocrine transition: Tumor plasticity under immunotherapy
Transición de CHC a tumor neuroendocrino: plasticidad tumoral bajo inmunoterapia
Read
437
Timeswas read the article
146
Total PDF
291
Total HTML
Share statistics
array:24 [ "pii" => "S0210570522000541" "issn" => "02105705" "doi" => "10.1016/j.gastrohep.2022.01.008" "estado" => "S300" "fechaPublicacion" => "2022-08-01" "aid" => "1916" "copyright" => "Elsevier España, S.L.U.. All rights reserved" "copyrightAnyo" => "2022" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Gastroenterol Hepatol. 2022;45:552-4" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "en" => array:19 [ "pii" => "S2444382422001419" "issn" => "24443824" "doi" => "10.1016/j.gastre.2022.01.003" "estado" => "S300" "fechaPublicacion" => "2022-08-01" "aid" => "1916" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Gastroenterol Hepatol. 2022;45:552-4" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Scientific letter</span>" "titulo" => "HCC-neuroendocrine transition: Tumor plasticity under immunotherapy" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "552" "paginaFinal" => "554" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Transición de CHC a tumor neuroendocrino: plasticidad tumoral bajo inmunoterapia" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1709 "Ancho" => 3175 "Tamanyo" => 1030584 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A–E (20×) Block cell from the baseline FNB showing an HCC in H&E (A), with positivity for hepatocyte markers (B, C) and negativity for synaptophysin (D). F–J (20×) Second liver biopsy showing a neuroendocrine carcinoma in H&E (F), with negativity for hepatocyte markers (G, H) and positivity for synaptophysin (I). (E and J) Ki67, showing a proliferation rate above 80% in the biopsy (J), much higher than in FNB (E).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Marco Sanduzzi-Zamparelli, Carla Fuster-Anglada, Jordi Bruix, Maria Reig, Alba Díaz" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Marco" "apellidos" => "Sanduzzi-Zamparelli" ] 1 => array:2 [ "nombre" => "Carla" "apellidos" => "Fuster-Anglada" ] 2 => array:2 [ "nombre" => "Jordi" "apellidos" => "Bruix" ] 3 => array:2 [ "nombre" => "Maria" "apellidos" => "Reig" ] 4 => array:2 [ "nombre" => "Alba" "apellidos" => "Díaz" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S0210570522000541" "doi" => "10.1016/j.gastrohep.2022.01.008" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210570522000541?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2444382422001419?idApp=UINPBA00004N" "url" => "/24443824/0000004500000007/v1_202208200553/S2444382422001419/v1_202208200553/en/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S0210570521000601" "issn" => "02105705" "doi" => "10.1016/j.gastrohep.2021.01.011" "estado" => "S300" "fechaPublicacion" => "2022-08-01" "aid" => "1768" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Gastroenterol Hepatol. 2022;45:555-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Image of the month</span>" "titulo" => "A rare cause of lower gastrointestinal bleeding: Pneumatosis cystoides intestinalis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "555" "paginaFinal" => "556" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Una causa rara de hemorragia digestiva baja: neumatosis cystoides intestinalis" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1298 "Ancho" => 2508 "Tamanyo" => 261573 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Abdominal CT images showing air-filled cysts within the bowel wall (arrows) of the descending colon.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Eduardo Dantas, Mariana Coelho, Cláudia Cardoso, Ana Paula Oliveira" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Eduardo" "apellidos" => "Dantas" ] 1 => array:2 [ "nombre" => "Mariana" "apellidos" => "Coelho" ] 2 => array:2 [ "nombre" => "Cláudia" "apellidos" => "Cardoso" ] 3 => array:2 [ "nombre" => "Ana Paula" "apellidos" => "Oliveira" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2444382422001353" "doi" => "10.1016/j.gastre.2021.01.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2444382422001353?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210570521000601?idApp=UINPBA00004N" "url" => "/02105705/0000004500000007/v1_202207130605/S0210570521000601/v1_202207130605/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0210570521003307" "issn" => "02105705" "doi" => "10.1016/j.gastrohep.2021.12.006" "estado" => "S300" "fechaPublicacion" => "2022-08-01" "aid" => "1903" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Gastroenterol Hepatol. 2022;45:543-51" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Adenosquamous cancer of the pancreas: A multicenter retrospective study" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "543" "paginaFinal" => "551" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Cancer adenoescamoso de pancreas. Estudio retrospectivo multicéntrico" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1348 "Ancho" => 2167 "Tamanyo" => 92208 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Disease free survival probability.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "José Manuel Ramia-Angel, Isabel Jaén-Torrejimeno, Alejandro Serrablo-Requejo, Gonzalo P. Rodríguez-Laiz, Diego López-Guerra, Teresa Abadía-Forcén, Cristina Alenda, Mario Serradilla-Martín, Gerardo Blanco-Fernández" "autores" => array:9 [ 0 => array:2 [ "nombre" => "José Manuel" "apellidos" => "Ramia-Angel" ] 1 => array:2 [ "nombre" => "Isabel" "apellidos" => "Jaén-Torrejimeno" ] 2 => array:2 [ "nombre" => "Alejandro" "apellidos" => "Serrablo-Requejo" ] 3 => array:2 [ "nombre" => "Gonzalo P." "apellidos" => "Rodríguez-Laiz" ] 4 => array:2 [ "nombre" => "Diego" "apellidos" => "López-Guerra" ] 5 => array:2 [ "nombre" => "Teresa" "apellidos" => "Abadía-Forcén" ] 6 => array:2 [ "nombre" => "Cristina" "apellidos" => "Alenda" ] 7 => array:2 [ "nombre" => "Mario" "apellidos" => "Serradilla-Martín" ] 8 => array:2 [ "nombre" => "Gerardo" "apellidos" => "Blanco-Fernández" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2444382422001407" "doi" => "10.1016/j.gastre.2021.12.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2444382422001407?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210570521003307?idApp=UINPBA00004N" "url" => "/02105705/0000004500000007/v1_202207130605/S0210570521003307/v1_202207130605/en/main.assets" ] "en" => array:15 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Scientific letter</span>" "titulo" => "HCC-neuroendocrine transition: Tumor plasticity under immunotherapy" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "552" "paginaFinal" => "554" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Marco Sanduzzi-Zamparelli, Carla Fuster-Anglada, Jordi Bruix, Maria Reig, Alba Díaz" "autores" => array:5 [ 0 => array:3 [ "nombre" => "Marco" "apellidos" => "Sanduzzi-Zamparelli" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">◊</span>" "identificador" => "fn0005" ] ] ] 1 => array:3 [ "nombre" => "Carla" "apellidos" => "Fuster-Anglada" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">◊</span>" "identificador" => "fn0005" ] ] ] 2 => array:3 [ "nombre" => "Jordi" "apellidos" => "Bruix" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 3 => array:4 [ "nombre" => "Maria" "apellidos" => "Reig" "email" => array:1 [ 0 => "mreig1@clinic.cat" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 4 => array:4 [ "nombre" => "Alba" "apellidos" => "Díaz" "email" => array:1 [ 0 => "madiaz@clinic.cat" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "BCLC Group, Liver Unit, Hospital Clínic of Barcelona, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "BCLC Group, Department of Pathology, Hospital Clinic of Barcelona, IDIBAPS, CIBERehd, University of Barcelona, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding authors." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Transición de CHC a tumor neuroendocrino: plasticidad tumoral bajo inmunoterapia" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1709 "Ancho" => 3175 "Tamanyo" => 1030584 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A–E (20×) Block cell from the baseline FNB showing an HCC in H&E (A), with positivity for hepatocyte markers (B, C) and negativity for synaptophysin (D). F–J (20×) Second liver biopsy showing a neuroendocrine carcinoma in H&E (F), with negativity for hepatocyte markers (G, H) and positivity for synaptophysin (I). (E and J) Ki67, showing a proliferation rate above 80% in the biopsy (J), much higher than in FNB (E).</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Case presentation</span><p id="par0005" class="elsevierStylePara elsevierViewall">A 75-years old male with history of arterial hypertension, hyperuricemia and liver cirrhosis due to hepatitis C virus infection was successfully treated in 2015 with direct antiviral agents. On October 2018 he was diagnosed by biopsy with hepatocellular carcinoma (HCC) of 60<span class="elsevierStyleHsp" style=""></span>mm in size in segment VIII. This was associated with vascular invasion of the right and medium hepatic veins (Barcelona Clinic Liver Cancer stage C<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a>) and the patient was included in a randomized controlled first line phase III trial receiving one dose of tremelimumab (anti-CTLA-4) followed by durvalumab (anti-PD-L1) every 4 weeks (<a href="ctgov:NCT03298451">NCT03298451</a>). Image assessment at 6 months documented partial response according to Response Evaluation Criteria in Solid Tumours v.1.1 due to size reduction in the target lesion (<span class="elsevierStyleItalic">nadir</span> of 34<span class="elsevierStyleHsp" style=""></span>mm, at month 21) and disappearance of vascular invasion. Furthermore, alpha-fetoprotein decreased from >5000 to 30<span class="elsevierStyleHsp" style=""></span>ng/mL at that time-point. At month 30, progressive disease due to size increase in the target lesion (63<span class="elsevierStyleHsp" style=""></span>mm in size) with invasion of inferior vena cava and of portal vein was observed. Treatment was interrupted and the patient was evaluated for a Second-Line Clinical Trial. Screening included tumor biopsy and the sample was reported as neuroendocrine carcinoma. A second biopsy was undertaken to obtain two tissue samples from two different parts of the nodule. Both tumor biopsies showed similar changes, consistent with an atypical epithelial proliferation arranged in solid nests and with focal central necrosis. The neoplastic cells showed conspicuous atypia, with abundant mitotic figures. Immunohistochemistry showed expression of broad-spectrum cytokeratin as well as neuroendocrine markers (chromogranin, synaptophysin and CD56), with a cell proliferation index (Ki67) of more than 80%. Hepatocytic markers were negative. Thus, the diagnosis of neuroendocrine carcinoma was unequivocally confirmed (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). The fine needle biopsy performed in 2018 was also reviewed and the baseline diagnosis of HCC was confirmed, without evidence of neuroendocrine differentiation.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0010" class="elsevierStylePara elsevierViewall">Upon diagnosis establishment the patient was scheduled for systemic therapy with carboplatin plus etoposide for neuroendocrine carcinoma and at the first image assessment a decrease in tumor size was observed.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Discussion</span><p id="par0015" class="elsevierStylePara elsevierViewall">Cancer lineage plasticity is a known phenomenon in the oncology realm. It reflects the capacity of a cell to transit into a new and different histological subtype.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a> Once it occurs, tumor plasticity generates intra-tumoral heterogeneity, thus playing a crucial role in therapy resistance and in metastatic dissemination.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a> In particular, the neuroendocrine transition represents the most known pathway of lineage plasticity in cancer and usually includes the adaptation of adenocarcinomas to more aggressive neuroendocrine phenotypes under therapy.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a> Around 5% of EGFR-mutant lung adenocarcinomas, and more than 20% of prostate adenocarcinomas treated with targeted therapies indeed present the transformation into the more aggressive neuroendocrine phenotype.<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">4,5</span></a> The current hypothesis of this transition suggests that genetic and epigenetic events promote lineage plasticity and trigger the intra-tumoral heterogeneity.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a> Subsequently a plasticity-permissive microenvironment, together with the treatment-exerted selective pressure prime the stem-cell phenotype acquisition and subsequently the transition into the new predominant histological clones.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a> Although the pre-treatment presence of scattered neuroendocrine cells into prostate cancer under androgen deprivation therapy has been reported to correlate with poor prognosis, the potential origin of neuroendocrine transition from these cells remains uncertain.</p><p id="par0020" class="elsevierStylePara elsevierViewall">It could be argued that our patient suffered from a false positive result of the initial tumor biopsy, but this is extremely unlikely. First, primary hepatic neuroendocrine tumors and neuroendocrine carcinomas of the liver are rare and HCC with neuroendocrine component are exceptionally rare. Second, in our case the tumor was well represented with the first biopsy so different parts of the nodule were assessed and if the neuroendocrine component would have existed, it could have been detected in the first biopsy.</p><p id="par0025" class="elsevierStylePara elsevierViewall">In conclusion, this case represents the first documented event of neuroendocrine transition in the setting of HCC. This observation is of utmost relevance considering that an immunotherapy-based regimens is included in the current standard of care for the systemic treatment of patients with HCC since 2020 and that the combination of tremelimumab with durvalumab has recently been announced to be superior in comparison to sorafenib in first-line (<a href="ctgov:NCT03298451">NCT03298451</a>). Both combinations obtain high rate of objective responses, but upon progression and consideration for Second-Line option, it seems worth to consider a new biopsy to rule out a major change in tumor phenotype that may mandate a completely different treatment approach. Accordingly, we strongly endorse recent tumor biopsy before starting a subsequent line of systemic therapy and even more, when patients are considered for recruitment into research trials.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Ethical considerations</span><p id="par0030" class="elsevierStylePara elsevierViewall">The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Funding</span><p id="par0035" class="elsevierStylePara elsevierViewall">MSZ: received grant support from <span class="elsevierStyleGrantSponsor" id="gs1">Instituto de Salud Carlos III</span> (<span class="elsevierStyleGrantNumber" refid="gs1">FI19/00222</span>).</p><p id="par0040" class="elsevierStylePara elsevierViewall">CFA: received grant support from <span class="elsevierStyleGrantSponsor" id="gs2">Contractes Clínic de Recerca “Emili Letang-Josep Font” 2020</span>, granted by Hospital Clínic de Barcelona.</p><p id="par0045" class="elsevierStylePara elsevierViewall">JB: received grant support from <span class="elsevierStyleGrantSponsor" id="gs3">Instituto de Salud Carlos III</span> (<span class="elsevierStyleGrantNumber" refid="gs3">PI18/00768</span>), the <span class="elsevierStyleGrantSponsor" id="gs4">Spanish Health Ministry (National Strategic Plan against Hepatitis C)</span>, AECC (<span class="elsevierStyleGrantNumber" refid="gs4">PI044031</span>) and WCR (AICR) 16-0026.</p><p id="par0050" class="elsevierStylePara elsevierViewall">MR: received grant support from <span class="elsevierStyleGrantSponsor" id="gs5">Instituto de Salud Carlos III</span> (<span class="elsevierStyleGrantNumber" refid="gs5">PI15/00145</span> and <span class="elsevierStyleGrantNumber" refid="gs5">PI18/0358</span>) and from the Spanish Health Ministry (National Strategic Plan against Hepatitis C).</p><p id="par0055" class="elsevierStylePara elsevierViewall">CIBERehd: is funded by the <span class="elsevierStyleGrantSponsor" id="gs6">Instituto de Salud Carlos III</span>.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conflict of interest</span><p id="par0060" class="elsevierStylePara elsevierViewall">MSZ: received speaker fees from Bayer and travel grants from Bayer, BTG and Eisai; JB: has consulted for Arqule, Bayer-Shering Pharma, Novartis, BMS, BTG-Biocompatibles, Eisai, Kowa, Terumo, Gilead, Bio-Alliance, Roche, AbbVie, MSD, Sirtex, Ipsen, Astra-Medimmune, Incyte, Quirem, Adaptimmune, Lilly, Basilea, Nerviano, Sanofi; and received research/educational grants from Bayer, and lecture fees from Bayer-Shering Pharma, BTG-Biocompatibles, Eisai, Terumo, Sirtex, Ipsen; MR: received consultancy fees and/or travel support from Bayer, BMS, Roche, Ipsen, AstraZeneca and Lilly, lecture fees from Bayer, BMS, Gilead, and Lilly and research grants from Bayer and Ipsen; AD: speaker fees from Bayer and travel grants from Bayer.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:6 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Case presentation" ] 1 => array:2 [ "identificador" => "sec0010" "titulo" => "Discussion" ] 2 => array:2 [ "identificador" => "sec0015" "titulo" => "Ethical considerations" ] 3 => array:2 [ "identificador" => "sec0020" "titulo" => "Funding" ] 4 => array:2 [ "identificador" => "sec0025" "titulo" => "Conflict of interest" ] 5 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:3 [ "etiqueta" => "◊" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">These authors equally contributed.</p>" "identificador" => "fn0005" ] ] "multimedia" => array:1 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1709 "Ancho" => 3175 "Tamanyo" => 1030584 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A–E (20×) Block cell from the baseline FNB showing an HCC in H&E (A), with positivity for hepatocyte markers (B, C) and negativity for synaptophysin (D). F–J (20×) Second liver biopsy showing a neuroendocrine carcinoma in H&E (F), with negativity for hepatocyte markers (G, H) and positivity for synaptophysin (I). (E and J) Ki67, showing a proliferation rate above 80% in the biopsy (J), much higher than in FNB (E).</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0030" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hepatocellular carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Forner" 1 => "M. Reig" 2 => "J. Bruix" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(18)30010-2" "Revista" => array:7 [ "tituloSerie" => "Lancet" "fecha" => "2018" "volumen" => "391" "numero" => "10127" "paginaInicial" => "1301" "paginaFinal" => "1314" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29307467" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0035" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Lineage plasticity in cancer: a shared pathway of therapeutic resistance" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Á. Quintanal-Villalonga" 1 => "J.M. Chan" 2 => "H.A. Yu" 3 => "D. Pe’er" 4 => "C.L. Sawyers" 5 => "T. Sen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/s41571-020-0340-z" "Revista" => array:6 [ "tituloSerie" => "Nat Rev Clin Oncol" "fecha" => "2020" "volumen" => "17" "paginaInicial" => "360" "paginaFinal" => "371" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32152485" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0040" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tumor plasticity and resistance to immunotherapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "L.A. Horn" 1 => "K. Fousek" 2 => "C. Palena" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.trecan.2020.02.001" "Revista" => array:6 [ "tituloSerie" => "Trends Cancer" "fecha" => "2020" "volumen" => "6" "paginaInicial" => "432" "paginaFinal" => "441" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32348738" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0045" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "N. Marcoux" 1 => "S.N. Gettinger" 2 => "G. O’Kane" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.18.01585" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2019" "volumen" => "37" "paginaInicial" => "278" "paginaFinal" => "285" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30550363" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0050" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of lineage plasticity to and from a neuroendocrine phenotype on progression and response in prostate and lung cancers" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M.A. Rubin" 1 => "R.G. Bristow" 2 => "P.D. Thienger" 3 => "C. Dive" 4 => "M. Imielinski" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.molcel.2020.10.033" "Revista" => array:6 [ "tituloSerie" => "Mol Cell" "fecha" => "2020" "volumen" => "80" "paginaInicial" => "562" "paginaFinal" => "577" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33217316" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/02105705/0000004500000007/v1_202207130605/S0210570522000541/v1_202207130605/en/main.assets" "Apartado" => array:4 [ "identificador" => "94062" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Carta científica" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/02105705/0000004500000007/v1_202207130605/S0210570522000541/v1_202207130605/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210570522000541?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 4 | 1 | 5 |
| 2024 October | 21 | 8 | 29 |
| 2024 September | 21 | 5 | 26 |
| 2024 August | 21 | 16 | 37 |
| 2024 July | 3 | 0 | 3 |
| 2024 June | 11 | 7 | 18 |
| 2024 May | 11 | 8 | 19 |
| 2024 April | 10 | 9 | 19 |
| 2024 March | 11 | 12 | 23 |
| 2024 February | 9 | 3 | 12 |
| 2024 January | 9 | 0 | 9 |
| 2023 December | 9 | 0 | 9 |
| 2023 November | 10 | 0 | 10 |
| 2023 October | 21 | 0 | 21 |
| 2023 September | 12 | 0 | 12 |
| 2023 August | 13 | 0 | 13 |
| 2023 July | 16 | 0 | 16 |
| 2023 June | 14 | 3 | 17 |
| 2023 May | 2 | 0 | 2 |
| 2023 April | 4 | 1 | 5 |
| 2023 March | 6 | 5 | 11 |
| 2023 February | 4 | 4 | 8 |
| 2023 January | 9 | 8 | 17 |
| 2022 December | 6 | 8 | 14 |
| 2022 November | 6 | 6 | 12 |
| 2022 October | 7 | 8 | 15 |
| 2022 September | 7 | 4 | 11 |
| 2022 August | 8 | 12 | 20 |
| 2022 July | 6 | 6 | 12 |
| 2022 May | 0 | 1 | 1 |
| 2022 April | 0 | 4 | 4 |
| 2022 March | 0 | 7 | 7 |
Show all
